Skip to main content

LANCE Ultra Human BCL-2 Detection Kit, 10,000 Assay Points

The LANCE® Ultra Human BCL-2 Detection Kit is designed for detection and quantitation of human Bcl-2 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

Feature Specification
Application Protein Quantification
Dynamic Range 168 - 100,000 pg/mL
Limit of Detection 168 pg/mL
Limit of Quantification 734 pg/mL
Sample Volume 15 µL

The LANCE® Ultra Human BCL-2 Detection Kit is designed for detection and quantitation of human Bcl-2 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

Product Variants
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Request More Information

Overview

The LANCE® Ultra Human BCL-2 Detection Kit is designed for detection and quantitation of human Bcl-2 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

  • No-wash steps, no separation steps
  • TR-FRET technology
  • Sensitive detection
  • High reproducibility
  • Faster time-to-results
  • Easy automation
  • 96-well, 384-well, and 1536-well formats

LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

Bcl-2 (B-cell lymphoma 2) is an oncogenic protein that inhibits apoptosis. It is a protein with a MW of 24-26 kDa, located within the mitochondrial membrane, endoplasmic reticulum and nuclear envelope. Bcl-2 is considered an important antiapoptotic protein and is thus classified as a proto-oncogene. Bcl-2 overexpression has been implicated in a wide variety of malignancies including (but not limited to) breast, prostate, skin, colon and pancreatic cancers as well as neurodegenerative and autoimmune diseases. Related anti-apoptotic proteins include Bcl-xL, Mcl-1 and Bcl-w. Proapoptotic proteins in the Bcl-2 family include Bax, BAD, Bak, Blk and Bid.

Specifications

Application
Protein Quantification
Automation Compatible
Yes
Brand
LANCE Ultra
Detection Modality
LANCE
Dynamic Range
168 - 100,000 pg/mL
Limit of Detection
168 pg/mL
Limit of Quantification
734 pg/mL
Product Group
Kit
Sample Volume
15 µL
Shipping Conditions
Shipped in Blue Ice
Target
Bcl2
Target Class
Biomarkers
Target Species
Human
Technology
TR-FRET
Therapeutic Area
Oncology
Unit Size
10,000 Assay Points

Resources

Are you looking for resources, click on the resource type to explore further.

1-2 of 2 Resources
Guide Icon
Guide
Download your guide about neurodegenerative diseases

Emerging pathways to neuroinflammation and neurodegeneration

Neurodegenerative diseases, such as amyotrophic lateral sclerosis...

Product Info Icon
Product Info
LANCE and LANCE Ultra TR-FRET technology product list

LANCE™ Ultra TR-FRET is a no-wash proximity assay technology that combines the benefits of time resolution (TR) with fluorescence...

Scroll Icon